Article info
PDFNeuromuscular
Original research
Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies
- Correspondence to Professor Eduardo Nobile-Orazio; eduardo.nobile{at}unimi.it
Citation
Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies
Publication history
- Received October 21, 2023
- Accepted February 13, 2024
- First published May 10, 2024.
Online issue publication
August 16, 2024
Article Versions
- Previous version (10 May 2024).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.